Use of genomic profiling to assess risk for cardiovascular disease and identify individualized prevention strategies-A targeted evidence-based review

Genetics in Medicine

Volumn 12, Issue 12, 2010, Pages 772-784

  Palomaki, Glenn E ^a,f   Melillo, Stephanie ^b,c   Neveux, Louis ^a   Douglas, Michael P ^b,c   Dotson, W David ^b   Janssens, A Cecile J W ^d   Balkite, Elizabeth A ^e   Bradley, Linda A ^a,b  

^a BROWN UNIVERSITY   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c McKing Consulting Corp   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ABQ Associates Inc   (United States)

^f WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

analytic validity; cardiovascular disease; clinical utility; clinical validity; evidence review; genomic profiles

Indexed keywords

ALLELE; ASSAY; BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL LABORATORY; CORONARY ARTERY DISEASE; DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA HYBRIDIZATION; EVIDENCE BASED MEDICINE; GENETIC MARKER; GENOMICS; HEART DISEASE; HEART INFARCTION; HUMAN; LABORATORY TEST; LIFESTYLE MODIFICATION; MEDICAL TECHNOLOGY; METHODOLOGY; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK ASSESSMENT; SCREENING; STROKE; SYSTEMATIC REVIEW; VALIDATION STUDY; VALIDITY;

CARDIOVASCULAR DISEASES; GENETIC MARKERS; GENETIC TESTING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 78650678672     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181f8728d     Document Type: Review

References (58)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009; 119:480-486.
2. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics- 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008;117:e25-e146.
3. Mensah GA, Ryan US, Hooper WC, et al. Vascular endothelium summary statement II: cardiovascular disease prevention and control. Vascul Pharmacol 2007;46:318-320.
4. Hobbs FD. Cardiovascular disease: different strategies for primary and secondary prevention? Heart 2004;90:1217-1223.
5. World Heart Association. Cardiovascular disease risk factors, 2009. Available at: http://www.worldheart.org/cardiovascular-health/cardiovascular- disease-risk-factors. Accessed June 12, 2009.
6. van Wyk JT, van Wijk MA, Sturkenboom MC, Moorman PW, van der Lei J. Identification of the four conventional cardiovascular disease risk factors by Dutch general practitioners. Chest 2005;128:2521-2527.
7. Clark LT, Ferdinand KC, Flack JM, et al. Coronary heart disease in African Americans. Heart Dis 2001;3:97-108.
8. American Heart Association. Heart disease & stroke statistics, 2009. 2009 update-at-a-glance. Available at: http://www.americanheart.org/ downloadable/ heart/1240250946756LS-1982%20Heart%20and%20Stroke%20Update.042009. pdf. Accessed July 8, 2010.
9. World Health Organization. International statistical classification of diseases and related health problems, 10th Revision. Version for 2007. Available at: http://www.who.int/classifications/icd/en/. Accessed January 12, 2009.
10. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006;355:2631-2639.
11. Casas JP, Cooper J, Miller GJ, Hingorani AD, Humphries SE. Investigating the genetic determinants of cardiovascular disease using candidate genes and meta-analysis of association studies. Ann Hum Genet 2006;70:145-169.
12. Pearson TA, Manolio TA. How to interpret a genome-wide association study. JAMA, 2008, 299, 1335-1344.
13. Humphries SE, Yiannakouris N, Talmud PJ. Cardiovascular disease risk prediction using genetic information (gene scores): is it really informative? Curr Opin Lipidol 2008;19:128-132.
14. Ioannidis JP. Personalized genetic prediction: too limited, too expensive, or too soon? Ann Intern Med 2009;150:139-141.
15. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
16. Watt A, Cameron A, Sturm L, et al. Rapid reviews versus full systematic reviews: an inventory of current methods and practice in health technology assessment. Int J Technol Assess Health Care 2008;24:133-139.
17. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, editors. Human Genome Epidemiology: a scientific foundation for using genetic information to improve health and prevent disease. Oxford: Oxford University Press, 2003:217-233.
18. U.S. National Library of Medicine. National Institutes of Health. PubMed. gov. Available at: http://preview.ncbi.nlm.nih.gov/pubmed, 2009. Accessed October 1, 2010.
19. HuGE Literature Finder. Available at: http://www.hugenavigator.net/ HuGENavigator/startPagePubLit.do, 2009. Accessed October 1, 2010.
20. Yu W, Wulf A, Yesupriya A, Clyne M, Khoury MJ, Gwinn M. HuGE Watch: tracking trends and patterns of published studies of genetic association and human genome epidemiology in near-real time. Eur J Hum Genet 2008;16:1155-1158.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
22. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008;37:120-132.
23. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. New York: John Wiley & Sons, Ltd., 2009.
24. Janssens AC, van Duijn CM. Five genetic variants associated with prostate cancer. N Engl J Med 2008;358:2739; author reply 2741.
25. Palomaki GE, Melillo S, Bradley LA. Association between 9p21 genomic markers and heart disease: a meta-analysis. JAMA 2010;303:648-656.
26. GeneTests. Available at: http://www.ncbi.nlm.nih.gov/sites/GeneTests, 2009.
27. CAP 2010 Surveys. Available at: http://viewer.zmags.com/publication/ f475b8bc#/f475b8bc/1, 2009. Accessed October 27, 2010.
28. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism, 2009. Evidence report/technology assessment no. 180 (Prepared by Johns Hopkins University Evidence Based Practice Center under contract no. HHSA 290-2007-10061-1). AHRQ Publication No. 09-E011. Rockville, MD: Agency for Healthcare Research and Quality. Accessed October 1, 2010.
29. Kim S, Misra A. SNP genotyping: technologies and biomedical applications. Annu Rev Biomed Eng 2007;9:289-320.
30. Ragoussis J. Genotyping technologies for genetic research. Annu Rev Genomics Hum Genet 2009;10:117-133.
31. Pompanon F, Bonin A, Bellemain E, Taberlet P. Genotyping errors: causes, consequences and solutions. Nat Rev Genet 2005;6:847-859.
32. Kutyavin IV, Milesi D, Belousov Y, et al. A novel endonuclease IV post-PCR genotyping system. Nucleic Acids Res 2006;34:e128.
33. Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ 1999;319:1562-1565.
34. Wald NJ, Morris JK, Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen 2005;12:197-201.
35. Anderson JL, Horne BD, Kolek MJ, et al. Genetic variation at the 9p21 locus predicts angiographic coronary artery disease prevalence but not extent and has clinical utility. Am Heart J 2008;156:1155.e2-1162.e2.
36. Talmud PJ, Cooper JA, Palmen J, et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem 2008;54:467-474.
37. Brautbar A, Ballantyne CM, Lawson K, et al. Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities Study. Circ Cardiovasc Genet 2009;2:279-285.
38. Paynter NP, Chasman DI, Buring JE, Shiffman D, Cook NR, Ridker PM. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med 2009;150:65-72.
39. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172; discussion 207-212.
40. Visel A, Zhu Y, May D, et al. Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature 2010;464:409-412.
41. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
42. Wang TJ. New cardiovascular risk factors exist, but are they clinically useful? Eur Heart J 2008;29:441-444.
43. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008;54:17-23.
44. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009;119:2408-2416.
45. Janssens AC, van Duijn CM. Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 2009;1:20.
46. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007; 316:1491-1493. (Pubitemid 46906618)
47. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science 2007;316: 1488-1491.
48. Kathiresan S, Voight BF, Purcell S, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009;41:334-341.
49. Sheridan SL, Crespo E. Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature. BMC Health Serv Res 2008;8:60.
50. King DE, Mainous AG 3rd, Carnemolla M, Everett CJ. Adherence to healthy lifestyle habits in US adults, 1988 -2006. Am J Med 2009;122:528-534.
51. Sposito AC, Ramires JA, Jukema JW, et al. Physicians' attitudes and adherence to use of risk scores for primary prevention of cardiovascular disease: cross-sectional survey in three world regions. Curr Med Res Opin 2009;25:1171-1178.
52. Schedlbauer A, Schroeder K, Fahey T. How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials. Fam Pract 2007;24:380-387.
53. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
54. van der Net JB, Janssens AC, Sijbrands EJ, Steyerberg EW. Value of genetic profiling for the prediction of coronary heart disease. Am Heart J 2009;158: 105-110.
55. Janssens AC, Gwinn M, Bradley LA, Oostra BA, van Duijn CM, Khoury MJ. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet 2008;82:593-599.
56. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003;33:177-182.
57. Ntzani EE, Rizos EC, Ioannidis JP. Genetic effects versus bias for candidate polymorphisms in myocardial infarction: case study and overview of large-scale evidence. Am J Epidemiol 2007;165:973-984.
58. NIH News, National Human Genome Research Institute. Study to probe how healthy younger adults make use of genetic tests, 2007. Available at: http://www.genome.gov/25521052. Accessed July 6, 2010.